A study found that blood pressure can drop upon standing in the first month after cellular therapies in a substantial share of recipients, underscoring the need for early monitoring protocols and risk stratification. Separately, researchers reported that blood-brain barrier disruption can distort brain tumor PET scans, complicating imaging interpretation in mouse models of glioblastoma. The work suggests that clinicians may need to account for BBB integrity when using PET signal as a proxy for tumor biology. Both findings affect how outcomes are assessed—orthostatic events for patient safety and PET imaging readouts for tumor evaluation—placing practical guardrails around current clinical and translational workflows.